{'fraction_non_alphanumeric': 0.023166023166023165, 'fraction_numerical': 0.007722007722007722, 'mean_word_length': 5.1726190476190474, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
SOP 07a: Monitoring of a Trial under CESAR Responsibility

Core ‘SOP 07: Data Flow, Monitoring, and Archiving’ was written under the assumption that a trial is sponsored by a pharmaceutical company that also takes the responsibility of monitoring according to Good Clinical Practice (GCP). The SOP 07a is a supplement to SOP 07 and describes the monitoring procedures in more detail. It is applicable if – The supplier of an investigational drug decides to contract the monitoring responsibility to CESAR, or if – CESAR decides to conduct a trial under its sole responsibility, including the sponsor responsibility of ensuring trial monitoring. The Chair of a CESAR working group in close cooperation with the Coordinating Investigator (CI) of a trial has to ensure that appropriately instructed, trained, and experienced persons, e.g. a clinical research associate or a research nurse with particular experience in the conduct of clinical trials according to GCP, are available to perform the monitoring activities defined in this SOP.